# Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma

> **NCT02655458** · PHASE1 · COMPLETED · sponsor: **Hearn Jay Cho** · enrollment: 15 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Elotuzumab
- **DRUG:** Lenalidomide
- **OTHER:** autologous PBMC reconstitution
- **OTHER:** ASCT

## Key facts

- **NCT ID:** NCT02655458
- **Lead sponsor:** Hearn Jay Cho
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2017-07-13
- **Final completion:** 2017-07-13
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2017-08-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02655458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02655458, "Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02655458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*